WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510343
Description: CIQ is a GluN2C/GluN2D subunit-selective NMDA receptor potentiator, which reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. The facilitation of GluN2C/GluN2D-containing receptors may serve as an important therapeutic strategy for treating positive and cognitive symptoms in schizophrenia.
MedKoo Cat#: 510343
Chemical Formula: C26H26ClNO5
Exact Mass: 467.14995
Molecular Weight: 467.94
Elemental Analysis: C, 66.73; H, 5.60; Cl, 7.58; N, 2.99; O, 17.10
CIQ is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
IUPAC/Chemical Name: (3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
InChi Key: VYMILMYEENZHAR-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H26ClNO5/c1-30-20-7-9-21(10-8-20)33-16-23-22-15-25(32-3)24(31-2)14-17(22)11-12-28(23)26(29)18-5-4-6-19(27)13-18/h4-10,13-15,23H,11-12,16H2,1-3H3
SMILES Code: O=C(C1=CC=CC(Cl)=C1)N2C(COC3=CC=C(OC)C=C3)C4=C(C=C(OC)C(OC)=C4)CC2
The following data is based on the product molecular weight 467.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kratz AL, Chadd E, Jensen MP, Kehn M, Kroll T. An examination of the psychometric properties of the community integration questionnaire (CIQ) in spinal cord injury. J Spinal Cord Med. 2014 Jan 3. [Epub ahead of print] PubMed PMID: 24621050.
2: Suryavanshi PS, Ugale RR, Yilmazer-Hanke D, Stairs DJ, Dravid SM. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br J Pharmacol. 2014 Feb;171(3):799-809. doi: 10.1111/bph.12518. PubMed PMID: 24236947; PubMed Central PMCID: PMC3969090.
3: Gontkovsky ST, Russum P, Stokic DS. Comparison of the CIQ and CHART Short Form in assessing community integration in individuals with chronic spinal cord injury: a pilot study. NeuroRehabilitation. 2009;24(2):185-92. doi: 10.3233/NRE-2009-0467. PubMed PMID: 19339757.
4: Kuipers P, Kendall M, Fleming J, Tate R. Comparison of the Sydney Psychosocial Reintegration Scale (SPRS) with the Community Integration Questionnaire (CIQ): psychometric properties. Brain Inj. 2004 Feb;18(2):161-77. PubMed PMID: 14660228.
5: Seale GS, Caroselli JS, High WM Jr, Becker CL, Neese LE, Scheibel R. Use of community integration questionnaire (CIQ) to characterize changes in functioning for individuals with traumatic brain injury who participated in a post-acute rehabilitation programme. Brain Inj. 2002 Nov;16(11):955-67. PubMed PMID: 12455520.
6: Shirai S, Tomita K, Furukawa F. Epidermal nuclear CIq deposits in a patient with amyopathic dermatomyositis. Eur J Dermatol. 1999 Mar;9(2):115-7. PubMed PMID: 10066959.